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The commonest cause for admission to hospital is acute painful or vaso-occlusive crisis, which accounts for 80% of all acute admissions; 12% of admissions are for acute chest syndrome.
Comparison of clinical features in Brent and in Jamaica shows that the Brent patients with homozygous sickle cell anaemia are admitted with painful crises more frequently than Jamaican patients. However, the frequency of admissions for chest syndrome and priapism, and the incidence of splenomegaly are similar. Leg ulcers are uncommon in Brent. Patients with sickle cell haemoglobin C disease appeared more severely affected in Jamaica than in Brent.
During the past two years 3165 newborn babies have been screened for sickle cell disease at the Central Middlesex Hospital: five babies with homozygous sickle cell anaemia and three babies with sickle cell haemoglobin C disease were detected. The overall incidence of sickle cell trait was 3*2% and of haemoglobin C trait 0-8%. A significant number of babies with sickle cell disease are born in London every year. It is essential that such babies are detected at birth and offered prophylaxis against pneumococcal infection, which is one of the major causes of infant mortality.
Sickle cell disease is becoming an important blood disease in Britain and firm guidelines for the management of acute and chronic complications are required.
Sickle cell disease is a collective term for a group of blood diseases resulting from the inheritance of haemoglobin S. The four main genotypes of sickle cell disease found in Britain are: homozygous sickle cell anaemia, sickle cell haemoglobin C disease, sickle cell beta+ thalassaemia (S/Beta+ thal), and sickle cell beta0 thalassaemia (S/Beta°thal). with the USA8 and Jamaican9 experience. As expected, the number of babies with sickle cell disease increases with the increasing percentage of black births.
In Jamaica the prevalence per 1000 births is 3-1 for SS, 2*0 for SC, 0-34 for S/Beta+ thal, and 0-16 for S/Beta°thal.9 The numbers screened in Brent are at present very small, but if the present trend continues the prevalence will be higher than in Jamaica (at present 7-7 for SS, 4 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) *Excluding admissions during pregnancy. tOnly patients followed for 3 years or more included. Table 5 ; these data confirm that SC is a milder disease than SS. Nevertheless, painful crises are not uncommon in SC, and the chest syndrome accounts for 12% of all admissions in both conditions. Infections and leg ulcers are rare in Britain. Few sequestration crises were seen, probably because the follow up did not Brozovic, Anionwu start until the second year of life or later in most patients (see Table 3 ).
The severity of the disease may also be assessed by the number of hospital admissions per year of follow up. This is shown in Table 6 Admissions for painful crises were required by more patients with SS in Brent than in Jamaica. The decision to admit is subjective and may not necessarily reflect the increased severity of vaso-occlusion. It is, however, interesting that fewer patients with SC needed admission for painful crisis in Brent than in Jamaica.
Similar percentages of patients with SS in both locations were admitted with chest syndrome; in SC chest syndrome was less common in Britain than in Jamaica. Leg ulcers were rare in Brent, but common in Jamaica. Splenomegaly was found in 14% of SS patients in England and in Jamaica, but was more common in Jamaican SC patients than in the Brent ones.
There were fewer pregnancies in Brent women with sickle cell disease than in their Jamaican coun- terparts, probably reflecting the altered social and reproductive pattern, as well as the relatively young mean age of the Brent group (21-9 for SS women and 26-3 for SC women).
The general impression is that the patients with SS in Britain have more vaso-occlusive crises but fewer cases of chest syndrome and leg ulcers. Patients with SC seem to be less severely affected in Britain than in Jamaica. The accuracy of these observations can be confirmed only by careful long term natural history studies, preferably on cohorts followed from birth. Such cohort studies are neither available nor planned in Britain.
Mortality
No data are available on the expected survival for patients with sickle cell disease in Britain. In the Jamaican cohort study Serjeant'°has shown a mortality of 10% in the first year of life, 5% in the second, and 3% in the third. He suggests that by the age of five the child may have survived the highest risk period and that the prognosis improves with age. Serjeant also states that "by the age of 20 years survival to 30 or 40 years may not be uncommon."
In the longitudinal study of 422 children in Los Angeles, Powars'6 calculated a 10% death rate during the first decade and 5% during each subsequent decade of life. Mann'7 followed 96 Birmingham children for 10 years and found an overall mortality of 1% per year. In the UK survey2 37 deaths were noted: 27 deaths were in SS patients (of the under 10s five died in the first two years of life and an additional 10 in the first decade) and 10 deaths were in SC patients (only in three under-lOs: one at the age of 2-5, and two at 6 and 7 years of age). It is a matter of utmost urgency that the British born babies with sickle cell disease are protected from the devastating infections and high early mortality. This has been successfully achieved in the USA' 18 and Jamaica'9 through a programme of newborn screening, antibiotic prophylaxis, and parental education.
A more specific determination of the interaction of sickle cell disease, in particular SS, with other genes, such as homozygous alpha thalassaemia or heterocellular persistence of haemoglobin F, is essential if we are to offer antenatal diagnosis. At the same time a systematic campaign of educating the sufferers, the community at risk, and the health professionals must be undertaken. As for the other inherited debilitating diseases, health, educational and social needs should be recognised and eventually met.
The size of the problem in Britain is often underestimated. For Sickle cell disease in Britain years ago. Although there are promising antisickling agents on the horizon, none is likely to be available immediately or to have a complete success in preventing all the manifestations of sickle cell disease. It therefore becomes increasingly important to establish firm guidelines for comprehensive management of sickle cell disease in Britain.
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